BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1334053)

  • 21. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
    André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
    Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Retrospective analysis of selected tumor markers (p53, PCNA, Ki67; DNA ploidy) and ultrastructure in patients with larynx carcinomas].
    Golusiñski W; Szmeja Z; Olofsson J; Biczysko W; Krygier-Stojałzowska A; Majewski P
    HNO; 1998 Mar; 46(3):233-40. PubMed ID: 9583028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA ploidy, P53 expression, and cellular proliferation in normal epithelium and squamous dysplasia of non-cancerous and cancerous human oesophagi.
    Itakura Y; Sasano F; Date F; Kato K; Sekine H; Mori S; Nagura H
    Anticancer Res; 1996; 16(1):201-8. PubMed ID: 8615609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung.
    Bellotti M; Elsner B; Paez De Lima A; Esteva H; Marchevsky AM
    Mod Pathol; 1997 Dec; 10(12):1221-7. PubMed ID: 9436967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study.
    Goukon Y; Sasano H; Nishihira T; Nagura H; Mori S
    Anticancer Res; 1994; 14(3B):1305-12. PubMed ID: 7915093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive analysis of selected diagnostic methods with respect to their usefulness in evaluating the biology of neoplastic cells in patients with laryngeal cancer.
    Golusinski W; Olofsson J; Szmeja Z; Biczysko W; Krygier-Stojałowska A; Kulczyński B
    Eur Arch Otorhinolaryngol; 1999; 256(6):306-11. PubMed ID: 10456281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colon cancer: p53 expression and DNA ploidy. Their relation to proximal or distal tumor site.
    García-Hirschfeld García J; Blanes Berenguel A; Vicioso Recio L; Márquez Moreno A; Rubio Garrido J; Matilla Vicente A
    Rev Esp Enferm Dig; 1999 Jul; 91(7):481-8. PubMed ID: 10477366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers.
    Simony J; Pujol JL; Radal M; Ursule E; Michel FB; Pujol H
    Cancer Res; 1990 Jul; 50(14):4382-7. PubMed ID: 2163748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas.
    Mørkve O; Laerum OD
    Cytometry; 1991; 12(5):438-44. PubMed ID: 1935458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.
    Fontanini G; Pingitore R; Bigini D; Vignati S; Pepe S; Ruggiero A; Macchiarini P
    Am J Pathol; 1992 Dec; 141(6):1285-90. PubMed ID: 1361306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.
    Korkolopoulou P; Oates J; Kittas C; Crocker J
    J Clin Pathol; 1994 Jan; 47(1):9-14. PubMed ID: 7907610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer].
    Kudela M; Pilka R; Lubuský M; Hejtmánek P; Dzubák P; Brychtová S
    Ceska Gynekol; 2011 Jun; 76(3):194-9. PubMed ID: 21838149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study.
    Casson AG; McCuaig S; Craig I; Ayed A; Inculet R; Kerkvliet N; O'Malley F
    J Surg Oncol; 1994 May; 56(1):13-20. PubMed ID: 8176935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas.
    Fléjou JF; Muzeau F; Potet F; Lepelletier F; Fékété F; Hénin D
    Pathol Res Pract; 1994 Dec; 190(12):1141-8. PubMed ID: 7540752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
    Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
    Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
    Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
    Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA aneuploidy, S-phase fraction and nuclear p53 positivity in non-small cell lung carcinoma.
    Pina TC; Zapata IT; López JB; Pérez JL; Paricio PP; Hernández PM
    Clin Biochem; 1999 Jul; 32(5):347-54. PubMed ID: 10480449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunochemical evidence of a mutated p53 protein expressed in human colorectal adenocarcinoma].
    Hammel PR; Beuvon FX; Salmon RJ; Remvikos Y
    Gastroenterol Clin Biol; 1991; 15(6-7):529-35. PubMed ID: 1916131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [DNA ploidy determination with flow cytometry, Ki-67 index and overexpression of p53 protein in 121 T1 superficial bladder carcinomas. Retrospective studies. Part II: Prognostic value and usefulness in the indication for prophylactic treatment with BCG].
    Moyano Calvo JL; De Miguel Rodríguez M; Poyato Galán JM; Ortíz Gamiz A; Molina Carranza A; Zerpa Railey JJ; Toro Cepeda H; Sánchez-Barriga Peña D; Galera Davidson H; Castiñeiras Fernández J
    Actas Urol Esp; 2001 Jan; 25(1):32-45. PubMed ID: 11284366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.